The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $80.91

Today's change-1.61 -1.95%
Updated January 19 4:00 PM EST. Delayed by at least 15 minutes.
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $80.91

Today's change-1.61 -1.95%
Updated January 19 4:00 PM EST. Delayed by at least 15 minutes.

Vertex Pharmaceuticals Inc crosses below 50-day moving average

Vertex Pharmaceuticals Inc closed sharply lower Thursday, dropping (U.S.)$1.61 or 1.95% to (U.S.)$80.91 and crossing below its 50-day moving average. Over the last five days, shares have lost 1.80% and 14.82% over the last 52 weeks. This security has underperformed the S&P 500 by 35.15% during the last year.

Key company metrics

  • Open(U.S.) $82.55
  • Previous close(U.S.) $82.52
  • High(U.S.) $82.72
  • Low(U.S.) $80.51
  • Bid / Ask(U.S.) $80.00 / (U.S.) $83.99
  • YTD % change+9.83%
  • Volume1,653,002
  • Average volume (10-day)2,067,269
  • Average volume (1-month)1,917,984
  • Average volume (3-month)1,973,968
  • 52-week range(U.S.) $71.46 to (U.S.) $103.73
  • Beta0.77
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward98.68×
  • Forward PEG1.50×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.90
Updated January 19 4:00 PM EST. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue414432398418
Total other revenue--------
Total revenue414432398418
Gross profit361387348356
Total cost of revenue53445062
Total operating expense433428412472
Selling / general / administrative10611210597
Research & development272271256310
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0012
Other operating expenses, total1111
Operating income-193-14-54
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-39-18-31-76
Income after tax-40-36-36-75
Income tax, total1185-1
Net income-39-65-42-74
Total adjustments to net income--------
Net income before extra. items-39-65-42-74
Minority interest1-28-61
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-39-65-42-74
Inc. avail. to common incl. extra. items-39-65-42-74
Diluted net income-39-65-42-74
Dilution adjustment--------
Diluted weighted average shares245244244243
Diluted EPS excluding extraordinary itemsvalue per share-0.16-0.26-0.17-0.30
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.16-0.26-0.17-0.30